Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition Linda VidarsdottirGudridur SteingrimsdottirJorunn Erla Eyfjord PRECLINICAL STUDIES 20 October 2010 Pages: 425 - 434
Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells Eun-Taex OhMoon-Taek ParkHeon Joo Park PRECLINICAL STUDIES 27 October 2010 Pages: 435 - 442
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP Nienke A. de VriesTessa BuckleOlaf van Tellingen PRECLINICAL STUDIES 21 October 2010 Pages: 443 - 449
Putative mechanisms of antitumor activity of cyano-substituted heteroaryles in HeLa cells Katja EsterFran SupekMarijeta Kralj PRECLINICAL STUDIES 03 November 2010 Pages: 450 - 467
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents Margaret E. MacyDeborah DeRyckereLia Gore PRECLINICAL STUDIES 03 November 2010 Pages: 468 - 479
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines Martin Schmidt-HieberRobert DabrowskiIgor W. Blau PRECLINICAL STUDIES 16 November 2010 Pages: 480 - 489
A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton Jin ZhangJing ZhouDuanqing Pei PRECLINICAL TRIALS 16 November 2010 Pages: 490 - 507
Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer Lixin MaHaiquan QiaoXueying Sun PRECLINICAL STUDIES 16 November 2010 Pages: 508 - 517
Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo Sun-Young HanChong Ock LeeJongkook Lee PRECLINICAL STUDIES 16 November 2010 Pages: 518 - 523
The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates AeRang KimCindy McCullyBrigitte C. Widemann PRECLINICAL STUDIES 12 November 2010 Pages: 524 - 528
The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines Miguel MuñozAna González-OrtegaRafael Coveñas PRECLINICAL STUDIES 01 December 2010 Pages: 529 - 540
Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL Rosario YerbesAbelardo López-Rivas PRECLINICAL STUDIES 25 November 2010 Pages: 541 - 547
Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway Chung Soo LeeEun-Ra JangMin Won Lee PRECLINICAL STUDIES 01 December 2010 Pages: 548 - 557
The curcuminoid CLEFMA selectively induces cell death in H441 lung adenocarcinoma cells via oxidative stress Kaustuv SahooMikhail G. DozmorovVibhudutta Awasthi PRECLINICAL STUDIES 22 December 2010 Pages: 558 - 567
Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride Kathryn A. SkeldingRichard D. BarryDarren R. Shafren PRECLINICAL STUDIES 21 December 2010 Pages: 568 - 581
Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms—action of two new agents Rajeev KumarVikas VermaGopal Gupta PRECLINICAL STUDIES 23 December 2010 Pages: 582 - 593
New Vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential Maria Teresa ConconiGiovanni MarzaroAdriana Chilin PRECLINICAL STUDIES 24 December 2010 Pages: 594 - 603
A phase I study of continuous infusion cilengitide in patients with solid tumors Peter H. O’DonnellSamir D. UndeviaMark J. Ratain PHASE I STUDIES 14 September 2010 Pages: 604 - 610
Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials Stephane EderhyChristophe MassardJean-Charles Soria PHASE I STUDIES 06 October 2010 Pages: 611 - 615
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Laura VidalMargarita MagemRamón Salazar PHASE I STUDIES 07 October 2010 Pages: 616 - 628
A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors Bhuvaneswari RamaswamyMitch A. PhelpsManisha H. Shah PHASE I STUDIES 12 October 2010 Pages: 629 - 638
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors Isamu OkamotoToshio ShimizuKazuhiko Nakagawa PHASE I STUDIES Open access 20 October 2010 Pages: 639 - 646
A phase I study of temsirolimus and metformin in advanced solid tumours Mary J. MacKenzieScott ErnstEric Winquist PHASE I STUDIES 27 October 2010 Pages: 647 - 652
Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials Nicolas PenelAlain DuhamelJacques Bonneterre PHASE I STUDIES 04 November 2010 Pages: 653 - 661
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist John W. BaumanJoyce M. AntalMaria Gutierrez PHASE I STUDIES 29 December 2010 Pages: 662 - 671
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy Sang Joon ShinJoong Bae AhnHyun Cheol Chung PHASE I STUDIES 29 December 2010 Pages: 672 - 680
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study Katalin BoérIstván LángElizabeth Murray PHASE II STUDIES 10 September 2010 Pages: 681 - 687
Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study Juan F. CuevaMarcos CalvoRafael López PHASE II STUDIES 16 September 2010 Pages: 688 - 694
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors Matthew D. GalskyDaniel D. Von HoffTal Z. Zaks PHASE II STUDIES 22 September 2010 Pages: 695 - 701
Treatment of bevacizumab-induced hypertension by amlodipine Olivier MirRomain CoriatFrançois Goldwasser PHASE II STUDIES 29 September 2010 Pages: 702 - 707
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine Takashi SasakiHiroyuki IsayamaKazuhiko Koike PHASE II STUDIES 06 October 2010 Pages: 708 - 713
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response Robert M. RifkinAndrew GreenspanRoy Beveridge PHASE II STUDIES 12 October 2010 Pages: 714 - 722
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study Robert J. Morgan JrLucille LeongJames H. Doroshow PHASE II STUDIES 09 October 2010 Pages: 723 - 728
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone Luis Paz-AresAntonio López-PousaJosé María Buesa PHASE II STUDIES 20 October 2010 Pages: 729 - 740
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial Tianhong LiScott D. ChristensenDavid R. Gandara PHASE II STUDIES Open access 22 October 2010 Pages: 741 - 748
Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium Ajjai AlvaSusan SlovinMaha Hussain PHASE II STUDIES 04 November 2010 Pages: 749 - 757
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies François GhiringhelliJulie VincentSylvain Ladoire PHASE II STUDIES 06 November 2010 Pages: 758 - 764
Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib Nathalie LassauLinda ChamiAxel Le Cesne PHASE II STUDIES 07 December 2010 Pages: 765 - 771
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer Stefan MadajewiczDavid M. WaterhouseSteven J. Nicol PHASE II STUDIES 01 December 2010 Pages: 772 - 778
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer Daniel J. RenoufMalcolm J. MooreLesley Seymour PHASE II STUDIES 18 December 2010 Pages: 779 - 786
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines Kohei ShitaraSatoshi YukiKei Muro PHASE II STUDIES 22 December 2010 Pages: 787 - 793
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate Justine Yang BruceJens EickhoffGlenn Liu PHASE II STUDIES 22 December 2010 Pages: 794 - 802
Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts Paola SecchieroFederica CoralliniGiorgio Zauli SHORT REPORT 09 September 2010 Pages: 803 - 807
Perirenal hematoma associated with bevacizumab treatment Hidetoshi HayashiIsamu OkamotoKazuhiko Nakagawa SHORT REPORT 24 September 2010 Pages: 808 - 809
The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL Francesco CarinciLorenzo MonastaPaola Secchiero SHORT REPORT 18 November 2010 Pages: 810 - 818
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients Dok Hyun YoonMin-Hee RyuYoon-Koo Kang SHORT REPORT 23 November 2010 Pages: 819 - 827
Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL Arianna GonelliOriano RadilloGian Maria Bonora SHORT REPORT 02 December 2010 Pages: 828 - 832
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model Angelica Linnea QuartinoLena E. FribergMats O. Karlsson SHORT REPORT 14 December 2010 Pages: 833 - 845
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells Cristina Oliveras-FerrarosAnna Massaguer Vall-lloveraJavier A. Menendez SHORT REPORT 16 December 2010 Pages: 846 - 852